Latest Articles

Publication Date
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results - Stocktwits

Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results Stocktwits

Published: July 2, 2025, 4:43 p.m.
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results - MSN

Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results MSN

Published: July 2, 2025, 3:55 p.m.
Organon halts development of endometriosis pain drug after trial failure By Investing.com - Investing.com Nigeria

Organon halts development of endometriosis pain drug after trial failure By Investing.com Investing.com Nigeria

Published: July 2, 2025, 12:52 p.m.
Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint - MarketScreener

Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint MarketScreener

Published: July 2, 2025, 12:10 p.m.
Organon halts development of endometriosis pain drug after trial failure By Investing.com - Investing.com Canada

Organon halts development of endometriosis pain drug after trial failure By Investing.com Investing.com Canada

Published: July 2, 2025, 12:08 p.m.
Organon to halt development of endometriosis pain drug after mid-stage trial failure - MarketScreener

Organon to halt development of endometriosis pain drug after mid-stage trial failure MarketScreener

Published: July 2, 2025, 11:52 a.m.
Organon abandons endometriosis pain drug development after trial failure - MarketScreener

Organon abandons endometriosis pain drug development after trial failure MarketScreener

Published: July 2, 2025, 11:52 a.m.
Organon halts development of endometriosis pain drug after trial failure - Investing.com

Organon halts development of endometriosis pain drug after trial failure Investing.com

Published: July 2, 2025, 11:42 a.m.
Aspira Loses $10M ARPA-H Contract but Vows to Continue Revolutionary Endometriosis Test Development - Stock Titan

Aspira Loses $10M ARPA-H Contract but Vows to Continue Revolutionary Endometriosis Test Development Stock Titan

Published: June 11, 2025, 12:30 p.m.
Development of a two-layer 3D equine endometrial tissue model using genipin-crosslinked collagen scaffolds and 3D printing - Nature

Development of a two-layer 3D equine endometrial tissue model using genipin-crosslinked collagen scaffolds and 3D printing Nature

Published: June 5, 2025, 10:08 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!